{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:46:11Z","timestamp":1793227571349,"version":"4.5.0"},"reference-count":46,"publisher":"Consilium Medicum","issue":"2","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Rebamipide is a cytoprotector developed in Japan where it has been successfully used for the treatment of stomach diseases for 30 years. Initially discovered effects of the drug included the induction of prostaglandins and the elimination of free oxygen radicals. Recent studies discovered new therapeutic targets of the drug, its new forms that made possible using rebamipid for the treatment of such diseases as NSAID enteropathy, ulcerative colitis, radiation colitis, pouchitis, enteropathy with impaired membrane digestion. It is used in endoscopy, ophthalmology, chemotherapy, rheumatology. The aim of this review is to present current information about the pharmacological and clinical feature of rebamipide and to study its therapeutic potential.<\/jats:p>","DOI":"10.26442\/00403660.2020.02.000569","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T14:35:20Z","timestamp":1593441320000},"page":"104-111","source":"Crossref","is-referenced-by-count":22,"title":["Pharmacological and clinical feature of rebamipide: new therapeutic targets"],"prefix":"10.26442","volume":"92","author":[{"given":"M. Yu.","family":"Zvyaglova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. V.","family":"Knyazev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. I.","family":"Parfenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18344","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Uchida M, Tabusa F, Komatsu M, et al. Studies on 2(1H)-quinolinone derivatives as gastric antiulcer active agents. 2-(4-chlorobenzoylamino)-3-[2(1H)quinolinon-4-yl] propionic acid related compounds. Chem Pharm Bull. 1985;33(9):3775-86.","DOI":"10.1248\/cpb.33.3775"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.34.4821"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Uchida M, Tabusa F, Komatsu M, et al. Studies on 2(1H)-quinolinone derivatives as gastric antiulcer active agents. Synthesis and antiulcer activity of optically active A-amino acid derivatives of 2(1H) quinolinone and oxindole. Chem Pharm Bull. 1987;35(2):853-6. doi: 10,1248\/cpb.35.853","DOI":"10.1248\/cpb.35.853"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c18-00629"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Kim KT, Lee JY, Park JH, et al. Capmul MCM\/Solutol HS15-Based Microemulsion for Enhanced Oral Bioavailability of Rebamipide. J Nanosci Nanotechnol. 2017 Apr;17(4):2340-344. doi:10.1166\/ jnn.2017.13314","DOI":"10.1166\/jnn.2017.13314"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200323120-00002"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1586\/egh.10.25"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Shioya Y, Shimizu T. High-performance liquid chromatographic procedure for the determination of a new anti-gastric ulcer agent, 2-(4-chlorobenzoylamino)-3[2(1H)-quinolinon-4-yl]propionic acid, in human plasma and urine. J Chromatogr. 1988;434(1):283-7. doi: 10.1016\/ 0378-4347(88)80089-6","DOI":"10.1016\/0378-4347(88)80089-6"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/00498250210130591"},{"key":"ref10","unstructured":"Arakawa T, Kobayashi K, Yoshikawa T. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43(9):5-13."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Nishizawa T, Suzuki H, Nakagawa I, et al. Rebamipide-promoted restoration of gastric mucosal sonic hedgehog expression after early Helicobacter pylori eradication. Digestion. 2009;79(4):259-62. doi: 10,1159\/000213241","DOI":"10.1159\/000213241"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FP0071422"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.08.140"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5009\/gnl17078"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1023\/b:ddas.0000017439.60943.5c"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200304010-00002"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2017.10.019"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.20626"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Murata H, Yabe Y, Tsuji S, et al. Gastro-protective agent rebamipide induces cyclooxygenease-2 (COX-2) in gastric epithelial cells. Dig Dis Sci. 2005;50:S70-S75. doi: 10,1007\/s10620-005-2809-0","DOI":"10.1007\/s10620-005-2809-0"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Santos MF, McCormack SA, Guo Z, et al. Rho proteins play a critical role in cell migration during the early phase of mucosal restitution. J Clin Invest. 1997;100:216-25. doi: 10,1172\/JCI119515","DOI":"10.1172\/JCI119515"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00371.2002"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i33.3802"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01074.x"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2006.04446.x"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Chitapanarux T, Praisontarangkul OA, Lertprasertsuke N. An open-labeled study of rebamipide treatment in chronic gastritis patients with dyspeptic symptoms refractory to proton pump inhibitors. Dig Dis Sci. 2008;53(11):2896-903. doi: 10,1007 \/ s10620-008-0255-5","DOI":"10.1007\/s10620-008-0255-5"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Du Y, Li Z, Zhan X, et al. Antiinflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China-STARS study. Dig Dis Sci. 2008;53(11):2886-95. doi: 10,1007 \/ s10620-007-0180-\u0433","DOI":"10.1007\/s10620-007-0180-z"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh201789284-90"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.26442\/terarkh201890827-32"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-007-2076-2"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-48173-6"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2606-0"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1159\/000495288"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.26442\/00403660.2019.02.000123"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2017.09.040"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122330"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.02.010"},{"key":"ref37","unstructured":"\u0425\u0430\u0442\u044c\u043a\u043e\u0432 \u0418.\u0415., \u041f\u0430\u0440\u0444\u0435\u043d\u043e\u0432 \u0410.\u0418., \u041a\u043d\u044f\u0437\u0435\u0432 \u041e.\u0412., \u0420\u0443\u0447\u043a\u0438\u043d\u0430 \u0418.\u041d., \u0410\u0442\u0440\u043e\u0449\u0435\u043d\u043a\u043e \u0410.\u041e., \u041c\u0438\u0445\u0430\u0439\u043b\u044f\u043d\u0446 \u0413.\u0421. \u0412\u043e\u0441\u043f\u0430\u043b\u0438\u0442\u0435\u043b\u044c\u043d\u044b\u0435 \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u044f \u043a\u0438\u0448\u0435\u0447\u043d\u0438\u043a\u0430 \u0432 \u043f\u0440\u0430\u0440\u043a\u0442\u0438\u043a\u0435 \u0442\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0430 \u0438 \u0445\u0438\u0440\u0443\u0440\u0433\u0430. \u041c.: \u0412\u0418\u0422\u0410-\u041f\u0420\u0415\u0421\u0421, 2017. 120 \u0441. [Khatkov IE, Parfenov AI, Knyazev OV, Ruchkina IN, Atroshchenko AO, Mikhailiants GS. Inflammatory bowel diseases in the practice of the therapist and surgeon: monograph. Series \u00abLibrary of the doctor\u00bb. Moscow: VITA-PRESS; 2017. 120 p. (In Russ.)]."},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Makiyama K, Takeshima F, Kawasaki H, Zea-Iriarte WL. Anti-inflammatory effect of rebamipide enema on proctitis type ulcerative colitis: a novel therapeutic alternative. Am J Gastroenterol. 2000;95:1838-9. doi: 10,1111\/j.1572-0241.2000.02154.x","DOI":"10.1111\/j.1572-0241.2000.02154.x"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-005-2816-1"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2006.04399.x"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i4.656"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.4059"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14021"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1006\/phrs.2000.0662"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-0942-5"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8145731"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33918\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/33918\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T20:59:08Z","timestamp":1634158748000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/33918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,27]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2020.02.000569","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"value":"2309-5342","type":"electronic"},{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,27]]}}}